ClinicalTrials.gg
CompletedNCT04683029Updated Jul 23, 2025Results posted

A Study of Guselkumab in Participants With Systemic Sclerosis

A Phase 2 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Scleroderma, Systemic, sponsored by Janssen Pharmaceutical K.K.. Completed at 4 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Scleroderma, Systemic by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Scleroderma, Systemic · Johnson & Johnson.

Started
2021
the only one that year
Phase 2
2 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Scleroderma, Systemic by Johnson & Johnson, this one is the only one that started in 2021, is one of 2 in phase 2, and was the 10th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

None of the 10 studies in Scleroderma, Systemic by Johnson & Johnson is open now. The open studies under Scleroderma, Systemic, anywhere →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Scleroderma, Systemic by Johnson & Johnson as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).

03

Conditions studied

  • Scleroderma, Systemic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of systemic sclerosis (SSc) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) 2013 criteria
  • Diffuse cutaneous SSc according to the LeRoy criteria that is, skin fibrosis proximal to the elbows and knees in addition to acral fibrosis
  • Disease duration of ≤36 months (defined as time from first non-Raynaud phenomenon manifestation).
  • Greater than or equal to (>=) 10 and less than or equal to (\<=) 22 modified Rodnan skin score (mRSS) units at screening and Week 0
  • Forced vital capacity (FVC) >= 60 percent (%) of predicted at screening
  • Diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted (-corrected) at screening.
  • Participants who meet 1 of the following criteria at screening: increase of >=3 mRSS units, compared with an assessment performed within the previous 2 to 6 months; Involvement of 1 new body area with an increase of >=2 mRSS units compared with an assessment performed within the previous 2 to 6 months; and Involvement of 2 new body areas with increase of >=1 mRSS units compared with the assessment within the previous 2 to 6 months

Exclusion criteria

Exclusion Criteria:

  • History of liver or renal insufficiency (estimated below 60 milliliter per minute [mL/min]); significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Has any known severe or uncontrolled SSc complications including hemoptysis, pulmonary hemorrhage, renal crisis
  • Has an interstitial lung disease requiring oxygen therapy
  • Has any rheumatic disease other than SSc such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), systemic lupus erythematosus, polymyositis/dermatomyositis that could interfere with assessment of SSc
  • Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances. (or, in the investigator's opinion, any other concomitant medical condition that places the participant at risk by participating in this study)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Group A: Guselkumab

    Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Guselkumab Dose 2 and IV injection of placebo at long-term extension (LTE) Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.

    Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2

  • Placebo comparator
    Group B: Placebo

    Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Placebo and IV injection of Guselkumab Dose 1 at LTE Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.

    Drug: Placebo

Interventions

  • Guselkumab Dose 1 will be administered intravenously.

  • Guselkumab Dose 2 will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered intravenously or subcutaneously.

06

What researchers measure

Primary outcomes

  1. Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24

    Change from baseline in mRSS at Week 24 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Main Study: Change From Baseline in Modified Rodnan Skin Score at Week 52

    Change from baseline in mRSS at Week 52 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

    Time frame: Baseline and Week 52

  2. Main Study: Percentage of Participants Who Experienced Worsening of Modified Rodnan Skin Score at Week 24 and Week 52

    The percentage of participants who experienced worsening of mRSS at Week 24 and Week 52 was reported. The worsening of mRSS was defined as an increase from baseline greater than or equal to (\>=) 5 points and \>=20 percent (%) in mRSS. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

    Time frame: Week 24 and Week 52

  3. Main Study: Percentage of Participants Who Achieved a Score of 0.6 in American College of Rheumatology Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (ACR CRISS) at Week 24 and Week 52

    ACR CRISS is a composite endpoint. Firstly, participants were evaluated on not-improved criterion: new onset of renal crisis, \>=15% decline in forced vital capacity \[FVC\] percent predicted relative to baseline, new onset of pulmonary arterial hypertension, and new onset of left ventricular failure. If yes, these participants were assigned probability score of 0.0. For remaining participants, percentage was based on CRISS domains: mRSS, FVC percent predicted, physician's global assessment, patient's global assessment and Health Assessment Questionnaire Disability-Index (HAQ-DI). Algorithm determines predicted probability of improvement from baseline by incorporating change in mRSS, FVC percent predicted, physician and patient global assessments and HAQ-DI. Outcome was a continuous variable between 0.0 and 1.0 (0 to 100%). Higher score=greater probability of improvement. ACR CRISS score \>=0.60 was considered improved, while predicted probability below 0.60 was considered not improved.

    Time frame: Week 24 and Week 52

  4. Main Study: Change From Baseline in Forced Vital Capacity (FVC) at Week 24 and Week 52

    FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.

    Time frame: Baseline, Week 24 and Week 52

  5. Main Study: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 24 and Week 52

    Change from baseline in the percent predicted FVC at Week 24 and Week 52 was reported. FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.

    Time frame: Baseline, Week 24 and Week 52

  6. Main Study: Change From Baseline in the Measured Absolute Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52

    DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.

    Time frame: Baseline, Week 24 and Week 52

  7. Main Study: Change From Baseline in the Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52

    Change from baseline in the percent predicted DLCO at Week 24 and Week 52 was reported. DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.

    Time frame: Baseline, Week 24 and Week 52

  8. Main Study: Change From Baseline in Digital Ulcer Counts at Week 24 and Week 52

    Digital ulcers were defined as a full thickness (\>3 millimeters \[mm\] in maximal diameter) skin lesion with loss of epithelium including lesions covered by eschar (excluding pitting scars and hyperkeratotic lesions). Healing was defined by re-epithelialization with loss of pain and exudate. The digital ulcer assessments and counting were performed by the investigator designee.

    Time frame: Baseline, Week 24 and Week 52

  9. Main Study: Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 and Week 52

    HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during past week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each activity category consisted of 2-3 items. For each item, level of difficulty was scored from 0 to 3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Total HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability.

    Time frame: Baseline, Week 24 and Week 52

  10. Main Study: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 24 and Week 52

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occur at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.

    Time frame: From Baseline (Week 0) up to Week 24 and Week 52

  11. Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occurred at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.

    Time frame: From Week 52 up to Week 112

  12. Main Study: Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 24 and Week 52

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.

    Time frame: From Baseline (Week 0) up to Week 24 and Week 52

  13. Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.

    Time frame: From Week 52 up to Week 112

  14. Main Study: Number of Participants With Adverse Events of Special Interest (AESI) Through Week 24 and Week 52

    AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.

    Time frame: From Baseline (Week 0) up to Week 24 and Week 52

  15. Long-term Extension (LTE) Period: Number of Participants With Adverse Events of Special Interest (AESI)

    AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.

    Time frame: From Week 52 up to Week 112

  16. Main Study: Serum Concentration of Guselkumab

    Serum concentration of guselkumab was reported. The lower limit of quantification (LLOQ) for guselkumab was 0.01 micrograms per milliliter (mcg/mL).

    Time frame: Pre-dose at Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and Post- dose at Weeks 0, 4, 8

  17. Long-term Extension (LTE) Study: Serum Concentrations of Guselkumab

    Serum concentration of guselkumab was reported. The LLOQ for guselkumab was 0.01 mcg/mL.

    Time frame: Pre-dose (at Weeks 56, 60, 64, 76, 88, 96) and Week 104

  18. Main Study: Number of Participants With Anti-Guselkumab Antibody

    Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.

    Time frame: From Baseline (Week 0) up to Week 52

  19. Long-term Extension (LTE) Study: Number of Participants With Anti-guselkumab Antibody

    Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.

    Time frame: From Week 52 up to Week 104

07

Results

Posted Oct 9, 2024

Participant flow

Participants diagnosed with systemic sclerosis as per American College of Rheumatology and European League Against Rheumatism 2013 criteria with disease duration of less than or equal to (\<=) 36 months and Modified Rodnan Skin Score ranged from greater than or equal to (\>=) 10 to less than or equal to (\<=) 22 units were randomized into the study.

Main Study: Week 0-Week 60
Participant flow — Main Study: Week 0-Week 60
MilestoneMain Study: Group A: GuselkumabMain Study: Group B: PlaceboLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
Started292700
Completed282700
Not completed1000
Withdrew: Withdrawal by subject1000
Long-term Extension(LTE):Week52-Week 112
Participant flow — Long-term Extension(LTE):Week52-Week 112
MilestoneMain Study: Group A: GuselkumabMain Study: Group B: PlaceboLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
Started002526
Completed002424
Not completed0012
Withdrew: Withdrawal by subject0002
Withdrew: Death0010

Outcome measures

PrimaryMain Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24

Change from baseline in mRSS at Week 24 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Score on a scale
Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24
Score on a scaleMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24-9.5 ± 0.743.1 ± 0.77
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · MMRM model · p = < 0.001 · Ls mean difference: -12.6 · 80% CI -13.8 to -11.4
SecondaryMain Study: Change From Baseline in Modified Rodnan Skin Score at Week 52

Change from baseline in mRSS at Week 52 was reported. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · Score on a scale
Main Study: Change From Baseline in Modified Rodnan Skin Score at Week 52
Score on a scaleMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Main Study: Change From Baseline in Modified Rodnan Skin Score at Week 52-9.3 ± 0.892.7 ± 0.93
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -12.0 · 80% CI -13.3 to -10.7
SecondaryMain Study: Percentage of Participants Who Experienced Worsening of Modified Rodnan Skin Score at Week 24 and Week 52

The percentage of participants who experienced worsening of mRSS at Week 24 and Week 52 was reported. The worsening of mRSS was defined as an increase from baseline greater than or equal to (\>=) 5 points and \>=20 percent (%) in mRSS. The mRSS is an accepted clinical measure of skin thickness. The investigator assessed the thickening of the skin using the mRSS through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each skin site was rated on a 0 to 3 scale; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness and unable to pinch. Individual skin scores in the 17 body areas were summed and defined as the total mRSS which ranged from 0 (no thickening) to 51 (severe thickening), where higher score indicated more severity of skin thickening/worst outcome.

Time frame:
Week 24 and Week 52
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Who Experienced Worsening of Modified Rodnan Skin Score at Week 24 and Week 52
Percentage of participantsMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 243.425.9
Week 5220.777.8
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Odds ratio (or): 0.1 · 80% CI 0.0 to 0.3
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Odds ratio (or): 0.1 · 80% CI 0.0 to 0.2
SecondaryMain Study: Percentage of Participants Who Achieved a Score of 0.6 in American College of Rheumatology Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (ACR CRISS) at Week 24 and Week 52

ACR CRISS is a composite endpoint. Firstly, participants were evaluated on not-improved criterion: new onset of renal crisis, \>=15% decline in forced vital capacity \[FVC\] percent predicted relative to baseline, new onset of pulmonary arterial hypertension, and new onset of left ventricular failure. If yes, these participants were assigned probability score of 0.0. For remaining participants, percentage was based on CRISS domains: mRSS, FVC percent predicted, physician's global assessment, patient's global assessment and Health Assessment Questionnaire Disability-Index (HAQ-DI). Algorithm determines predicted probability of improvement from baseline by incorporating change in mRSS, FVC percent predicted, physician and patient global assessments and HAQ-DI. Outcome was a continuous variable between 0.0 and 1.0 (0 to 100%). Higher score=greater probability of improvement. ACR CRISS score \>=0.60 was considered improved, while predicted probability below 0.60 was considered not improved.

Time frame:
Week 24 and Week 52
Reported as:
Number · Percentage of participants
Main Study: Percentage of Participants Who Achieved a Score of 0.6 in American College of Rheumatology Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (ACR CRISS) at Week 24 and Week 52
Percentage of participantsMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 2486.23.7
Week 5279.33.7
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Odds ratio (or): 203.2 · 80% CI 42.1 to 980.6
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Odds ratio (or): 130.3 · 80% CI 28.2 to 601.9
SecondaryMain Study: Change From Baseline in Forced Vital Capacity (FVC) at Week 24 and Week 52

FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Least squares mean · Liters
Main Study: Change From Baseline in Forced Vital Capacity (FVC) at Week 24 and Week 52
LitersMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 24-51.9 ± 33.91-4.7 ± 35.78
Week 52-26.5 ± 30.42-12.3 ± 32.15
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -47.2 · 80% CI -96.8 to 2.4
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -14.2 · 80% CI -57.2 to 28.8
SecondaryMain Study: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 24 and Week 52

Change from baseline in the percent predicted FVC at Week 24 and Week 52 was reported. FVC was the total amount of air (in liters) exhaled from the lungs during the lung function test measured by spirometer which assessed the change in lung function related to the disease status of an underlying interstitial lung disease.

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Least squares mean · Percent predicted FVC
Main Study: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 24 and Week 52
Percent predicted FVCMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 24-0.7 ± 1.21-0.7 ± 1.26
Week 52-0.2 ± 1.17-0.4 ± 1.22
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -0.0 · 80% CI -1.7 to 1.6
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: 0.1 · 80% CI -1.4 to 1.7
SecondaryMain Study: Change From Baseline in the Measured Absolute Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52

DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Least squares mean · Milliliter/minute/millimeter mercury
Main Study: Change From Baseline in the Measured Absolute Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52
Milliliter/minute/millimeter mercuryMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 24-0.60 ± 0.257-0.51 ± 0.265
Week 52-0.35 ± 0.316-0.56 ± 0.327
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -0.08 · 80% CI -0.44 to 0.27
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: 0.21 · 80% CI -0.29 to 0.71
SecondaryMain Study: Change From Baseline in the Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52

Change from baseline in the percent predicted DLCO at Week 24 and Week 52 was reported. DLCO is a measurement of the ability of the lungs to transfer gases from the air to the blood. DLCO is measured using the single breath method. Participants breathe in (inhale) air containing a very small, harmless amount of a tracer gas, such as carbon monoxide. Participants hold their breath for 10 seconds, then rapidly blow it out (exhale). The exhaled gas was tested to determine amount of the tracer gas absorbed during the breath.

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Least squares mean · Percent predicted DLCO
Main Study: Change From Baseline in the Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) at Week 24 and Week 52
Percent predicted DLCOMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 24-4.57 ± 1.338-2.49 ± 1.347
Week 52-1.71 ± 1.541-1.85 ± 1.565
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -2.08 · 80% CI -3.81 to -0.34
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: 0.14 · 80% CI -2.13 to 2.42
SecondaryMain Study: Change From Baseline in Digital Ulcer Counts at Week 24 and Week 52

Digital ulcers were defined as a full thickness (\>3 millimeters \[mm\] in maximal diameter) skin lesion with loss of epithelium including lesions covered by eschar (excluding pitting scars and hyperkeratotic lesions). Healing was defined by re-epithelialization with loss of pain and exudate. The digital ulcer assessments and counting were performed by the investigator designee.

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Least squares mean · Ulcers
Main Study: Change From Baseline in Digital Ulcer Counts at Week 24 and Week 52
UlcersMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 24-0.0 ± 0.474.8 ± 0.48
Week 52-0.1 ± 0.554.1 ± 0.58
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -4.9 · 80% CI -5.7 to -4.0
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -4.3 · 80% CI -5.1 to -3.5
SecondaryMain Study: Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 and Week 52

HAQ-DI assessed the degree of difficulty participants experienced in 8 daily living activity domains during past week: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each activity category consisted of 2-3 items. For each item, level of difficulty was scored from 0 to 3 (0=no difficulty, 1=some difficulty, 2=much difficulty, 3=unable to do). Total HAQ-DI score was computed as the sum of domain scores divided by the number of domains answered, providing a score from 0 (no difficulty) to 3 (maximum difficulty), where higher score indicated greater disability.

Time frame:
Baseline, Week 24 and Week 52
Reported as:
Least squares mean · Score on a scale
Main Study: Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 and Week 52
Score on a scaleMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 24-0.0529 ± 0.090620.3477 ± 0.09439
Week 52-0.0572 ± 0.089550.1782 ± 0.09321
Statistical analysis
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -0.4006 · 80% CI -0.5344 to -0.2668
  • Main Study: Group A: Guselkumab vs Main Study: Group B: Placebo · Ls mean difference: -0.2355 · 80% CI -0.3730 to -0.0980
SecondaryMain Study: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 24 and Week 52

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occur at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.

Time frame:
From Baseline (Week 0) up to Week 24 and Week 52
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 24 and Week 52
ParticipantsMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 242024
Week 522526
SecondaryLong-term Extension (LTE) Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs that occurred at or after the initial administration of study intervention. All TEAEs including serious and non-serious events are reported in this outcome measure.

Time frame:
From Week 52 up to Week 112
Reported as:
Count of participants · Participants
Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)2325
SecondaryMain Study: Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 24 and Week 52

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.

Time frame:
From Baseline (Week 0) up to Week 24 and Week 52
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 24 and Week 52
ParticipantsMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 2400
Week 5211
SecondaryLong-term Extension (LTE) Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity, or resulted in congenital anomaly/birth defect. TEAEs were defined as AEs that occur at or after the initial administration of study intervention.

Time frame:
From Week 52 up to Week 112
Reported as:
Count of participants · Participants
Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
Long-term Extension (LTE) Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)10
SecondaryMain Study: Number of Participants With Adverse Events of Special Interest (AESI) Through Week 24 and Week 52

AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.

Time frame:
From Baseline (Week 0) up to Week 24 and Week 52
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Adverse Events of Special Interest (AESI) Through Week 24 and Week 52
ParticipantsMain Study: Group A: GuselkumabMain Study: Group B: Placebo
Week 2400
Week 5212
SecondaryLong-term Extension (LTE) Period: Number of Participants With Adverse Events of Special Interest (AESI)

AESI were defined as any newly identified malignancy or case of active tuberculosis (TB) or interstitial lung disease (ILD) occurring after the first study intervention administration in study participants and was reported by the investigator to the sponsor or designee within 24 hours after being made aware of the event. AESIs for this study included drug-induced liver injuries, active TB, ILD, hypersensitivity reaction, opportunistic infection and adverse cardiovascular events.

Time frame:
From Week 52 up to Week 112
Reported as:
Count of participants · Participants
Long-term Extension (LTE) Period: Number of Participants With Adverse Events of Special Interest (AESI)
ParticipantsLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
Long-term Extension (LTE) Period: Number of Participants With Adverse Events of Special Interest (AESI)00
SecondaryMain Study: Serum Concentration of Guselkumab

Serum concentration of guselkumab was reported. The lower limit of quantification (LLOQ) for guselkumab was 0.01 micrograms per milliliter (mcg/mL).

Time frame:
Pre-dose at Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and Post- dose at Weeks 0, 4, 8
Reported as:
Mean · mcg/mL
Main Study: Serum Concentration of Guselkumab
mcg/mLMain Study: Group A: Guselkumab
Pre-dose at Week 0NA ± NA
Post-dose at Week 0140.880 ± 26.5879
Pre-dose at Week 422.489 ± 6.9499
Post-dose at Week 4160.691 ± 31.7578
Pre-dose at Week 827.968 ± 9.7988
Post-dose at Week 8164.633 ± 28.9999
Pre-dose at Week 1236.497 ± 13.7929
Pre-dose at Week 1621.697 ± 9.6355
Pre-dose at Week 2012.751 ± 6.0638
Pre-dose at Week 2413.981 ± 6.6055
Pre-dose at Week 2814.184 ± 5.6980
Pre-dose at Week 3212.564 ± 5.6367
Pre-dose at Week 3612.932 ± 6.4345
Pre-dose at Week 4013.375 ± 6.1989
Pre-dose at Week 4412.469 ± 6.8698
Pre-dose at Week 4812.074 ± 6.1027
Pre-dose at Week 5211.363 ± 6.6822
SecondaryLong-term Extension (LTE) Study: Serum Concentrations of Guselkumab

Serum concentration of guselkumab was reported. The LLOQ for guselkumab was 0.01 mcg/mL.

Time frame:
Pre-dose (at Weeks 56, 60, 64, 76, 88, 96) and Week 104
Reported as:
Mean · mcg/mL
Long-term Extension (LTE) Study: Serum Concentrations of Guselkumab
mcg/mLLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
Pre-dose at Week 5612.167 ± 5.475319.285 ± 8.3377
Pre-dose at Week 6012.704 ± 5.694225.925 ± 10.9856
Pre-dose at Week 6413.835 ± 7.332633.368 ± 14.8075
Pre-dose at Week 7611.641 ± 5.574613.200 ± 6.0810
Pre-dose at Week 8810.339 ± 5.120911.893 ± 6.3203
Pre-dose at Week 9610.082 ± 4.537112.426 ± 5.6925
Week 10410.080 ± 5.259612.301 ± 6.0099
SecondaryMain Study: Number of Participants With Anti-Guselkumab Antibody

Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.

Time frame:
From Baseline (Week 0) up to Week 52
Reported as:
Count of participants · Participants
Main Study: Number of Participants With Anti-Guselkumab Antibody
ParticipantsMain Study: Group A: Guselkumab
Main Study: Number of Participants With Anti-Guselkumab Antibody6
SecondaryLong-term Extension (LTE) Study: Number of Participants With Anti-guselkumab Antibody

Number of participants with anti-guselkumab antibody were reported. Serum samples were assessed for anti-drug antibodies.

Time frame:
From Week 52 up to Week 104
Reported as:
Count of participants · Participants
Long-term Extension (LTE) Study: Number of Participants With Anti-guselkumab Antibody
ParticipantsLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
Long-term Extension (LTE) Study: Number of Participants With Anti-guselkumab Antibody60

Adverse events

Collected over All-cause mortality: Main Study: From screening (Week [-6]) up to Week 60 and LTE Period: From Week 52 up to Week 112 ; SAEs and Non-serious AEs: Main Study: From baseline (Week 0) up to Week 60; LTE Period: From Week 52 up to Week 112. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study: Group A: Guselkumab0/29 (0%)1/29 (3.4%)22/29 (75.9%)
Main Study: Group B: Placebo0/27 (0%)1/27 (3.7%)26/27 (96.3%)
LTE Period: Group A: Guselkumab Then Guselkumab1/25 (4%)1/25 (4%)22/25 (88%)
LTE Period: Group B: Placebo Then Guselkumab0/26 (0%)0/26 (0%)22/26 (84.6%)
Most frequent serious events
Most frequent serious events
EventMain Study: Group A: GuselkumabMain Study: Group B: PlaceboLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
MyocarditisCardiac disorders0/290/271/250/26
Covid-19Infections and infestations0/291/270/250/26
Ileus ParalyticGastrointestinal disorders1/290/270/250/26
Pneumatosis IntestinalisGastrointestinal disorders1/290/270/250/26
Systemic SclerodermaMusculoskeletal and connective tissue disorders1/290/270/250/26
Most frequent other events
Showing 10 of 37
Most frequent other events
EventMain Study: Group A: GuselkumabMain Study: Group B: PlaceboLTE Period: Group A: Guselkumab Then GuselkumabLTE Period: Group B: Placebo Then Guselkumab
PyrexiaGeneral disorders9/2914/274/257/26
NasopharyngitisInfections and infestations6/292/2712/259/26
Covid-19Infections and infestations2/292/277/256/26
Neutrophil Count DecreasedInvestigations0/297/270/250/26
White Blood Cell Count DecreasedInvestigations0/297/270/250/26
ArthralgiaMusculoskeletal and connective tissue disorders2/297/271/251/26
EczemaSkin and subcutaneous tissue disorders0/297/271/250/26
ParonychiaInfections and infestations4/295/272/252/26
Dermatitis ContactSkin and subcutaneous tissue disorders5/294/270/252/26
InfluenzaInfections and infestations0/290/270/254/26

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Main Study: Group A: GuselkumabMain Study: Group B: PlaceboTotal
Mean51.3 ± 13.2650.8 ± 12.1851.1 ± 12.64
Age, Customized
Age, Customized(Participants)Main Study: Group A: GuselkumabMain Study: Group B: PlaceboTotal
18 to 64 years252348
65 years and over448
Sex: Female, Male
Sex: Female, Male(Participants)Main Study: Group A: GuselkumabMain Study: Group B: PlaceboTotal
Female262147
Male369
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Study: Group A: GuselkumabMain Study: Group B: PlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino282755
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Study: Group A: GuselkumabMain Study: Group B: PlaceboTotal
American Indian or Alaska Native000
Asian282755
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Main Study: Group A: GuselkumabMain Study: Group B: PlaceboTotal
JAPAN292756
08

Study locations

4 sites
  • Chukyo Hospital
    Aichi, 457 8510, Japan
  • The University of Tokyo Hospital
    Tokyo, 113-8655, Japan
  • Wakayama Medical University Hospital
    Wakayama, 641 8510, Japan
  • University of Fukui Hospital
    Yoshida, 910-1193, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2023, 26 months.

Results were first posted in Oct 2024, 1 year 4 months after primary completion.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Dec 24, 2020
StartActual
Feb 24, 2021
Primary completionActual
May 17, 2023
CompletionActual
Jul 9, 2024
Results first posted
Oct 9, 2024
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04683029
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Feb 24, 2021
Primary completion
May 17, 2023
Completion
Jul 9, 2024
Results posted
Oct 9, 2024
Last update
Jul 23, 2025

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion